Coinfection with HCV and HIV is common and an increasingly important public health problem. Management of hepatitis C in HIV-infected patients is complicated by immune suppression, potential drug interactions and toxicities, and the relative paucity of health-care providers with expertise in the management of both diseases. Data now support the safety, tolerability and efficacy of hepatitis C treatment with peginterferon plus ribavirin in HIV-infected patients.
